Support Care Cancer 2017 Feb 22. Epub 2017 Feb 22.
Oral Medicine Department, Institut Claudius Regaud, Institut Universitaire du cancer Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex, France.
Development of biological targeted therapies and immune checkpoint inhibitors has redefined the treatment for many cancers; however, the increasing use of new protocols has led to physicians observing a new spectrum of toxicities. To date, oral adverse events induced by these new anticancer therapies have been mainly reported using nonspecific terminology ("stomatitis," "mucosal inflammation," "mucositis") and remain poorly characterized, with the exception of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis. Oral toxicities of targeted therapies often display very characteristic features which clearly differ from classic oral injuries observed with cytotoxic chemotherapy and/or radiotherapy. Read More